Hypocalcemia associated with strontium-89 administration in a patient with diffuse bone metastases from neuroendocrine carcinoma.
Metastatic bone disease is often associated with severe pain in cancer patients, and has become an increasingly important quality-of-life issue. Radionuclides, such as strontium-89 (Sr-89), have provided effective palliation of metastatic bone pain. Although strontium follows the biochemical pathways of calcium in the body, changes in calcium homeostasis related to Sr-89 therapy have rarely been reported. We present a case of a 32-year-old male with poorly differentiated neuroendocrine carcinoma and extensive skeleton metastases who developed profound hypocalcemia after Sr-89 administration.
Mori
Masanori
M
Department of Palliative Care and Rehabilitation Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Fadul
Nada A
NA
Bruera
Eduardo
E
Dalal
Shalini
S
D000328:Adult; D001859:Bone Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D006934:Hypercalcemia / Q000175:diagnosis / Q000209:etiology*; D008297:Male; D018358:Neuroendocrine Tumors / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D011832:Radiation Injuries / Q000175:diagnosis / Q000209:etiology*; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use*
D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes